A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer
Phase of Trial: Phase I/II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Pazopanib (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms TOPAZ
- 07 Jun 2017 Biomarkers information updated
- 17 Feb 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 17 Feb 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov.